Article info

Download PDFPDF

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

Authors

  1. a 732-235-7701 hk553{at}cinj.rutgers.edu
  2. b jeffery.russell{at}immunocore.com
  3. c ohamid{at}theangelesclinic.org
  4. d sbhatia{at}uw.edu
  5. e patrick.terheyden{at}uksh.de
  6. f dangelos{at}mskcc.org
  7. g kshih{at}tnonc.com
  8. h celeste.lebbe{at}sls.aphp.fr
  9. i michelemilella{at}hotmail.com
  10. j isaac.brownell{at}nih.gov
  11. k karl.lewis{at}ucdenver.edu
  12. l jochen_lorch{at}dfci.harvard.edu
  13. m anja.von.heydebreck{at}merckgroup.com
  14. n meliessa.hennessy{at}emdserono.com
  15. o pnghiem{at}uw.edu
View Full Text

Citation

Kaufman HL, Russell JS, Hamid O, et al
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

Publication history

  • Received October 26, 2017
  • Accepted December 12, 2017
  • First published January 19, 2018.
Online issue publication 
January 19, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.